{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:01:00Z","timestamp":1769122860062,"version":"3.49.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7,1]]},"DOI":"10.1093\/infdis\/jit122","type":"journal-article","created":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T05:07:44Z","timestamp":1364360864000},"page":"32-39","source":"Crossref","is-referenced-by-count":100,"title":["Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine\/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1\u2013Infected Patients: Week 48 Results"],"prefix":"10.1093","volume":"208","author":[{"given":"Joel E.","family":"Gallant","sequence":"first","affiliation":[]},{"given":"Ellen","family":"Koenig","sequence":"additional","affiliation":[]},{"given":"Jaime","family":"Andrade-Villanueva","sequence":"additional","affiliation":[]},{"given":"Ploenchan","family":"Chetchotisakd","sequence":"additional","affiliation":[]},{"given":"Edwin","family":"DeJesus","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Antunes","sequence":"additional","affiliation":[]},{"given":"Keikawus","family":"Arast\u00e9h","sequence":"additional","affiliation":[]},{"given":"Graeme","family":"Moyle","sequence":"additional","affiliation":[]},{"given":"Giuliano","family":"Rizzardini","sequence":"additional","affiliation":[]},{"given":"Jan","family":"Fehr","sequence":"additional","affiliation":[]},{"given":"Yapei","family":"Liu","sequence":"additional","affiliation":[]},{"given":"Lijie","family":"Zhong","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Callebaut","sequence":"additional","affiliation":[]},{"given":"Javier","family":"Szwarcberg","sequence":"additional","affiliation":[]},{"given":"Martin S.","family":"Rhee","sequence":"additional","affiliation":[]},{"given":"Andrew K.","family":"Cheng","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2013,3,26]]},"reference":[{"key":"key\n\t\t\t\t20170511122049_JIT122C1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","article-title":"Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents","volume":"35","author":"Hsu","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20170511122049_JIT122C2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1021\/ml1000257","article-title":"Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer","volume":"1","author":"Xu","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"key\n\t\t\t\t20170511122049_JIT122C3","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1097\/QAD.0b013e32834b4d48","article-title":"Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine\/tenofovir df in the initial treatment of HIV infection","volume":"25","author":"Elion","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170511122049_JIT122C4","volume-title":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","author":"US Department of Health and Human Services"},{"key":"key\n\t\t\t\t20170511122049_JIT122C5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel","volume":"308","author":"Thompson","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170511122049_JIT122C6","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170511122049_JIT122C7","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"DeJesus","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170511122049_JIT122C8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511122049_JIT122C9","volume-title":"Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements","author":"US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research"},{"key":"key\n\t\t\t\t20170511122049_JIT122C10","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/QAD.0b013e32830285fb","article-title":"Efficacy and safety of once-daily darunavir\/ritonavir versus lopinavir\/ritonavir in treatment-naive HIV-1-infected patients at week 48","volume":"22","author":"Ortiz","year":"2008","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170511122049_JIT122C11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","article-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study","volume":"372","author":"Molina","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170511122049_JIT122C12","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/QAD.0b013e328345766f","article-title":"Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for the initial treatment of HIV infection","volume":"25","author":"Cohen","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170511122049_JIT122C13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/QAI.0b013e3182645648","article-title":"Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function","volume":"61","author":"German","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170511122049_JIT122C14","article-title":"Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters [abstract A1\u20131724]","author":"Lepist","year":"2011"},{"key":"key\n\t\t\t\t20170511122049_JIT122C15","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/QAD.0b013e328339fe53","article-title":"Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients","volume":"24","author":"Mocroft","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170511122049_JIT122C16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/QAD.0b013e32834f337c","article-title":"Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir","volume":"26","author":"Young","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170511122049_JIT122C17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-154-7-201104050-00316","article-title":"Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1","volume":"154","author":"Daar","year":"2011","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170511122049_JIT122C18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1310\/hct0904-213","article-title":"Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF\/emtricitabine given once daily","volume":"9","author":"Elion","year":"2008","journal-title":"HIV Clin Trials"},{"key":"key\n\t\t\t\t20170511122049_JIT122C19","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/QAD.0b013e32832cbcc2","article-title":"Randomized, double-blind, placebo-matched, multicenter trial of abacavir\/lamivudine or tenofovir\/emtricitabine with lopinavir\/ritonavir for initial HIV treatment","volume":"23","author":"Smith","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170511122049_JIT122C20","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","article-title":"Once-daily darunavir\/ritonavir vs. lopinavir\/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis","volume":"23","author":"Mills","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170511122049_JIT122C21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.qai.0000242449.67155.1a","article-title":"A once-daily lopinavir\/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen","volume":"43","author":"Johnson","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170511122049_JIT122C22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAI.0b013e318198a815","article-title":"Gemini: a noninferiority study of saquinavir\/ritonavir versus lopinavir\/ritonavir as initial HIV-1 therapy in adults","volume":"50","author":"Walmsley","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170511122049_JIT122C23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3851\/IMP1745","article-title":"Nevirapine versus atazanavir\/ritonavir, each combined with tenofovir disoproxil fumarate\/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial","volume":"16","author":"Soriano","year":"2011","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170511122049_JIT122C24","article-title":"Renal function in treatment-naive subjects exposed to tenofovir\/emtricitabine in combination with atazanavir\/ritonavir or lopinavir\/ritonavir: 48-week results from the CASTLE study (BMS AI424138)[THPE0190]","author":"McGrath","year":"2008"},{"key":"key\n\t\t\t\t20170511122049_JIT122C25","article-title":"Renal function in treatment-naive subjects exposed to tenofovir\/emtricitabine in combination with atazanavir\/ritonavir or lopinavir\/ritonavir: 48-week results from the CASTLE study (BMS AI424138)","author":"da Silva","year":"2008"},{"key":"key\n\t\t\t\t20170511122049_JIT122C26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1742-6405-5-5","article-title":"Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir\/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT","volume":"5","author":"Smith","year":"2008","journal-title":"AIDS Res Ther"},{"key":"key\n\t\t\t\t20170511122049_JIT122C27","volume-title":"Viread (tenofovir disoproxil fumarate) US prescribing information","author":"Gilead Sciences"},{"key":"key\n\t\t\t\t20170511122049_JIT122C28","article-title":"Effect of acid reducing agents on the relative bioavailability and pharmacokinetics of cobicistat-boosted elvitegravir [abstract P_13]","author":"Mathias"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/208\/1\/32\/16867038\/jit122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T16:40:05Z","timestamp":1503506405000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1093\/infdis\/jit122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,26]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,3,26]]},"published-print":{"date-parts":[[2013,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jit122","relation":{},"ISSN":["1537-6613","0022-1899"],"issn-type":[{"value":"1537-6613","type":"electronic"},{"value":"0022-1899","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3,26]]}}}